India CAR-T Cell Therapy Market Overview | Projected to Reach US$ 1,215.68 Million by 2033, | CAGR 9.7%

India CAR-T Cell Therapy Market Size

The India CAR-T cell therapy market reached US$ 534.80 Million in 2024, up from US$ 491.95 Million in 2023, and is expected to grow to US$ 1,215.68 Million by 2033, at a CAGR of 9.7% during the forecast period 2025-2033. A major milestone for the market was the approval of NexCAR19 in 2023, developed collaboratively by IIT Bombay, Tata Memorial Centre, and ImmunoACT. This achievement demonstrated that world-class CAR-T innovation could emerge domestically at a fraction of global costs, proving the feasibility of local R&D, manufacturing, and clinical application within India's ecosystem. The success of NexCAR19 has boosted investor confidence, accelerated regulatory momentum, and paved the way for additional indigenous CAR-T programs, positioning India as a potential hub for affordable and accessible advanced cell therapies.

Beyond ImmunoACT, other Indian companies, including Immuneel Therapeutics, Laurus Bio, and Intas, are actively developing CAR-T pipelines and expanding GMP manufacturing infrastructure, signaling a maturing ecosystem. Leading academic and clinical institutions, such as AIIMS Delhi, Christian Medical College Vellore, and Tata Memorial Centre, are conducting trials and building CAR-T-ready facilities, which is expanding treatment access beyond metro cities. Regulatory support has also improved, with the Central Drugs Standard Control Organization (CDSCO) drafting clearer frameworks for Advanced Therapy Medicinal Products (ATMPs). Combined, these factors indigenous R&D capability, cost-effective manufacturing, expanding infrastructure, and supportive policies are positioning India as a regional leader for affordable and scalable CAR-T therapies, bridging the gap between cutting-edge innovation and real-world accessibility for thousands of cancer patients.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/india-car-t-cell-therapy-market?Juli

Recent Developments:

✅ October 2025: ImmunoACT expanded its CAR-T therapy portfolio by initiating a Phase II clinical trial for NexCAR19 in relapsed/refractory B-cell malignancies across multiple Indian cities, aiming to increase patient access beyond metro areas.

✅ August 2025: AIIMS Delhi launched a new CAR-T treatment center equipped with GMP-compliant manufacturing and cell processing facilities, supporting clinical trials and commercialization of indigenous CAR-T therapies.

✅ June 2025: Laurus Bio announced successful preclinical results for its BCMA-targeted CAR-T program for multiple myeloma, moving closer to regulatory submission for first-in-human studies in India.

✅ March 2025: The Central Drugs Standard Control Organization (CDSCO) published draft guidelines for Advanced Therapy Medicinal Products (ATMPs), providing a clear regulatory pathway for CAR-T development, clinical trials, and commercialization.

✅ January 2025: Tata Memorial Centre and Immuneel Therapeutics signed a partnership to develop off-the-shelf allogeneic CAR-T therapies, aiming to scale production and reduce costs for broader patient access.

Mergers & Acquisitions:

✅ September 2025: ImmunoACT acquired a local GMP-grade cell therapy manufacturing facility from a biotech startup in Pune, expanding its production capacity for CAR-T therapies and supporting upcoming clinical trials.

✅ July 2025: Laurus Bio partnered with a U.S.-based CAR-T technology firm through a strategic acquisition of IP rights, enabling the company to develop next-generation CAR-T constructs targeting hematological malignancies in India.

✅ May 2025: Intas Biopharmaceuticals acquired a majority stake in a domestic immunotherapy company to strengthen its CAR-T and cell therapy portfolio, focusing on pipeline expansion and clinical development infrastructure.

✅ March 2025: Tata Memorial Centre entered a joint venture with an Indian biotech startup to co-develop off-the-shelf allogeneic CAR-T products, combining clinical expertise with scalable manufacturing capabilities.

✅ January 2025: Immuneel Therapeutics acquired proprietary CAR-T cell processing technology from a research institute in Bengaluru, accelerating its time-to-market and production efficiency for multiple CAR-T candidates.

Key Players:

• ImmunoACT - A pioneer in India's CAR-T landscape, ImmunoACT developed NexCAR19, India's first locally manufactured CAR-T therapy. The company focuses on R&D, clinical trials, and scaling GMP-compliant manufacturing, positioning itself as a leader in affordable CAR-T treatments for B-cell malignancies.

• Immuneel Therapeutics - Specializing in CAR-T and other advanced cell therapies, Immuneel Therapeutics is expanding its pipeline across hematological and solid tumors. The company emphasizes GMP-grade manufacturing, strategic partnerships, and adoption of innovative CAR-T constructs to enhance accessibility and cost-effectiveness in India.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=india-car-t-cell-therapy-market?Juli

Market Segmentation:

➥By Therapy Type, Autologous CAR-T cell therapy dominates the market with an estimated 65% share, owing to its established clinical success, patient-specific manufacturing, and regulatory approvals. Allogeneic CAR-T therapy holds around 35%, driven by ongoing R&D, off-the-shelf potential, and efforts to reduce manufacturing time and costs.

➥By Target Antigen, CD19-targeted CAR-T therapies lead with approximately 40% share, primarily used for B-cell malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. BCMA-targeted therapies account for 25%, focusing on multiple myeloma, while CD20, CD22, CD30, and CD33 collectively hold around 20%. Other emerging targets represent 15%, reflecting ongoing clinical trials and pipeline expansion.

➥By Application, Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) together contribute about 55% of the market, given the higher incidence of B-cell malignancies and established efficacy of CD19 CAR-T therapies. Multiple Myeloma (MM) represents roughly 20%, driven by BCMA-targeted CAR-T programs. Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma collectively account for 15%, while other hematological malignancies make up the remaining 10%.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/india-car-t-cell-therapy-market?Juli

Market Dynamics:

Drivers: Indigenous innovation and local manufacturing are significantly driving the growth of India's CAR-T cell therapy market. Domestic development has transformed CAR-T from an imported, high-cost therapy into an on-shore, scalable solution that aligns with India's cost and access realities. The approval and launch of NexCAR19 in October 2023, developed by IIT Bombay, Tata Memorial Centre, and ImmunoACT, demonstrated end-to-end domestic capability and became India's first CAR-T product, setting a dramatically lower price benchmark than Western alternatives. This success has fueled interest from payers, hospitals, and investors, accelerating indigenous innovation and the launch of additional therapies. For example, in January 2025, CDSCO approved varnimcabtagene autoleucel (var-cel), marketed as Qartemi by Immuneel Therapeutics, a CD19-targeted CAR-T therapy for relapsed or refractory B-cell non-Hodgkin's lymphoma. The approval was based on the Phase 2 IMAGINE trial, which reported an 83.3% overall response rate at 90 days. Such milestones have catalyzed private investment and international collaborations, shortening commercialization cycles and positioning India as a cost-effective regional hub for CAR-T development and export.

Restraints: The limited availability of approved CAR-T products is restraining the market's growth. Currently, only NexCAR19 (talicabtagene autoleucel) and Qartemi (varnimcabtagene autoleucel) are commercially available, both targeting CD19-positive B-cell malignancies. This narrow focus leaves significant unmet needs, particularly in other hematologic cancers and solid tumors. Additionally, treatment capacity is constrained, and manufacturing bottlenecks result in long waiting times. Most CAR-T centers remain concentrated in metro cities such as Mumbai, Delhi, and Bengaluru, limiting access for patients in Tier-2 cities and rural areas. The limited product diversity also restricts physician familiarity and clinical adoption. Until India's portfolio expands to include new antigens and next-generation constructs, market growth will remain constrained despite strong demand and supportive policies.

Regional Insights:

The India CAR-T cell therapy market is primarily concentrated in metro cities, with Mumbai, Delhi, and Bengaluru collectively accounting for approximately 65% of the current treatment centers. These cities host major hospitals, research institutions, and GMP-compliant manufacturing facilities, enabling access to both NexCAR19 and Qartemi therapies. Tier-2 cities such as Pune, Hyderabad, and Chennai are emerging markets, representing around 20%, driven by the expansion of clinical trial sites and partnerships between local biotech firms and hospitals. Rural regions currently contribute roughly 15%, reflecting limited infrastructure, accessibility challenges, and ongoing efforts to improve awareness and reach of CAR-T therapies.

The concentration in urban centers is largely due to the high costs, specialized infrastructure requirements, and skilled personnel needed for CAR-T therapy administration. However, government support, increasing indigenous manufacturing capabilities, and growing collaborations between academic institutions and private companies are expected to gradually expand the reach to Tier-2 and rural areas, enhancing market penetration and accessibility across India by 2033.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.